Prevalence of SARS-COV-2 antibodies in the Thomayer University Hospital staff after the first wave of COVID-19
Authors:
M. Ibrahimová 1
; V. Jamriková 2; P. Sojka 1; Z. Khaznadar 1; K. Bořecká 2
Authors place of work:
Imunologická laboratoř, Fakultní Thomayerova nemocnice, Praha
1; Oddělení klinické biochemie, Fakultní Thomayerova nemocnice, Praha
2
Published in the journal:
Epidemiol. Mikrobiol. Imunol. 71, 2022, č. 1, s. 3-8
Category:
Original Papers
Summary
Objectives: To map the prevalence of SARS-CoV-2 antibodies in the staff of the Thomayer University Hospital in Prague following the first wave of COVID-19. The main reason was the large number of COVID-19 patients admitted to the Thomayer University Hospital with confirmed SARS-CoV-2 infection.
Material and Methods: A volunteer study based on a questionnaire survey and determination of total antibodies (ECLIA, Roche) and individual classes of immunoglobulins (ELISA IgG and IgA, Euroimmun).
Results: The study involved 808 employees, 2/3 of whom were from clinical departments. Fifteen participants, predominantly nurses (n = 12), tested ECLIA positive for antibodies against SARS-CoV-2 and ELISA positive or borderline positive for IgG antibodies. Positive or borderline IgA antibodies were recorded in 12 subjects. Most of the positive study participants (n = 13) contracted the SARS-CoV-2 virus at the workplace after repeated contact with positive patients. Most subjects infected (n = 12) had a more severe course but did not require hospitalization. We detected only one asymptomatic antibody-positive person.
Conclusions: After the first wave of COVID-19, SARS-CoV-2 antibodies were only demonstrated in 1.9% of the Thomayer University Hospital employees tested. In clinical departments, the positivity rate was 2.3%, and in non-clinical departments, it was only 0.5%. The low prevalence of antibodies points to the low number of infected hospital staff and a very good level of compliance with all public health and epidemiological measures.
Keywords:
health professionals – Antibodies – SARS-CoV-2 – COVID-19 – prevalence
Zdroje
1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J., 2020;43(4):328–333.
2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med., 2020;382(13):1199–1207.
3. Bchetnia M, Girard C, Duchaine C, et al. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS- -CoV-2): A review of the current global status. J Infect Public Health, 2020;13(11):1601–1610.
4. Sagnelli C, Celia B, Monari C, et al. Management of SARS-CoV-2 pneumonia [published online ahead of print, 2020 Aug 28]. J Med Virol., 2020;10.1002/jmv.26470.
5. Prather KA, Wang CC, Schooley RT. Reducing transmission of SARS-CoV-2. Science, 2020;368(6498):1422–1424.
6. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA, 2020;323(15):1488–1494.
7. Komenda M, Karolyi M, Bulhart V, et al. COVID‑19: Přehled aktuální situace v ČR. Onemocnění aktuálně [online]. Praha: Ministerstvo zdravotnictví ČR, 2020 [cit. 12.12.2020]. Dostupné na www:www:<https:// onemocneni-aktualne.mzcr.cz/covid-19. ISSN 2694-9423.
8. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med., 2020;173(5):362– 367.
9. Nikolai LA, Meyer CG, Kremsner PG, et al. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. Int J Infect Dis., 2020;100:112–116.
10. Studie kolektivní imunity SARS-CoV-2-CZ-Preval [online]. Praha: ÚZIS ČR, 2020. Dostupné na www:<https://covid-imunita.uzis.cz/.
11. Malickova K, Kratka Z, Luxova S, et al. Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics? Scand J Gastroenterol., 2020;55(8):917–919.
12. Krátká Z, Luxová Š, Malíčková K, et al. Testing for COVID-19: a few points to remember. Testování COVID-19 – co bychom měli mít na paměti. Cas Lek Cesk., 2020;159(2):72–77.
13. Elecsys Anti-SARS-CoV-2. Příbalová informace, 2020-11, V3.0; Material Numbers 09203095190.
14. EUROIMMUN Anti-SARS-CoV-2 ELISA IgG. Příbalová informace El_2606G_A_CZ_ C04.docx Verze: 2020-05-07.
15. EUROIMMUN Anti-SARS-CoV-2 ELISA IgA. Příbalová informace El_2606A_A_CZ_ C04.docx Verze: 2020-05-07.
16. Krátká Z, Fürst T. Světlo na konci tunelu? Počet lidí s protilátkami proti koronaviru v ČR rychle stoupá. ,Dostupné na www:<https://prolekare.cz/.
17. Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA, 2020;324(2):195–197.
18. Jeremias A, Nguyen J, Levine J, et al. Prevalence of SARS-CoV-2 Infection Among Health Care Workers in a Tertiary Community ,Hospital [published online ahead of print, 2020 Aug 11]. JAMA ,Intern Med., 2020;e204214.
19. Plebani M, Padoan A, Fedeli U, et al. SARS-CoV-2 serosurvey in health care workers of the Veneto Region. Clin Chem Lab Med., 2020;58(12):2107–2111.
20. Bořecká K, Jamriková V, Sojka P, et al. Stanovení protilátek anti- SARS-CoV-2 nukleokapsid versus spike, ECLIA versus ELISA. Klin Biochem Metab., 2021;29(1):19–24.
21. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev., 2020;6(6):CD013652. Published 2020 Jun 25.
22. Wellinghausen N, Plonné D, Voss M, et al. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. J Clin Virol., 2020;130:104542.
23. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol., 2020;5(52):eabe5511. doi:10.1126/sciimmunol. abe5511.
24. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med., 2020;173(4):262–267.
25. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest., 2020;130(10):5235–5244.
26. Goetz L, Yang J, Greene W, et al. A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies. J Appl Lab Med., 2020;5(6):1401–1405.
27. Döhla M, Boesecke C, Schulte B, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health, 2020;182:170–172.
Štítky
Hygiene and epidemiology Medical virology Clinical microbiologyČlánok vyšiel v časopise
Epidemiology, Microbiology, Immunology
2022 Číslo 1
Najčítanejšie v tomto čísle
- Next generation probiotics: an overview of the most promising candidates
- Overview of basic epidemiological characteristics and descriptive analysis of the incidence of human yersiniosis in the Czech Republic in 2018–2020
- Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic
- Prevalence of SARS-COV-2 antibodies in the Thomayer University Hospital staff after the first wave of COVID-19